The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …

Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune
response associated with immunological memory, provided they display sufficient …

Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade. …

A better understanding of human hepatocellular carcinoma (HCC) pathogenesis at the
molecular level will facilitate the discovery of tumor-initiating events. Transcriptome sequencing …

Immunotherapy is revolutionizing the clinical management of multiple tumors. However,
only a fraction of patients with cancer responds to immunotherapy, and currently available …

Background To understand the involvement of micro-RNA (miRNA) in the development and
progression of oesophageal squamous cell carcinoma (ESCC), miRNA profiles were …

Single-cell RNA sequencing has enabled the decomposition of complex tissues into
functionally distinct cell types. Often, investigators wish to assign cells to cell types through …

Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, …

Background Immune checkpoint inhibitors are effective cancer treatments, but molecular
determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies …

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we
describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic …